The standard systemic therapy is dependent on the breast cancer subtype, including chemotherapy alone for TNBC, endocrine therapy which is the cornerstone of HER2−/ER+/PR+ breast cancer, and immunotherapy (i.e., trastuzumab and pertuzumab) for HER2+ breast cancer. Here, ERBB2 is linked to breast carcinoma.